Fig. 1
From: Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing
PEGASUS whole-genome plasma sequencing approach and molecular properties of cfDNA. a Workflow for the PEGASUS whole-genome plasma DNA sequencing approach. b Distribution of total cfDNA concentrations (nanograms) in the prostate cancer patients, with the dotted line showing the QC threshold (< 2 ng). c Comparison of cfDNA concentrations (ng/mL) between diploid and aneuploid genomic cfDNA profiles. d Distribution of cfDNA fragment sizes (bp). e Comparison of the distribution of cfDNA fragment sizes in basepairs between diploid and aneuploid genomic cfDNA profiles. f Distribution of the somatic mutation allele frequencies (MAFs) among the 23 plasma and 9 metastatic tissue samples. Significance in c and e was calculated using the Wilcoxon rank sum test. Red dots in c and e represent mean values